NEW YORK, November 21, 2017 /PRNewswire/ --
According to a report by Global Market Insights, Inc., the Biotechnology Market size will exceed USD 775.2 billion with 9.9% CAGR from 2016 to 2024. Based on technology, the industry is segmented into tissue
engineering and regeneration, fermentation, PCR, nanobiotechnology, chromatography, DNA sequencing, and more. In recent years,
the tissue engineering and regeneration segment accounted for highest revenue and was valued at over USD
104.5 billion. However, the nanobiotechnology, fermentation and cell based assay segments will experience strong growth
thanks to rising R&D investments by various biotechnological and pharmaceutical companies. Cosmos Holdings Inc. (OTC: COSM),
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), CASI Pharmaceuticals, Inc. (NASDAQ: CASI), Protalix BioTherapeutics, Inc.
(NYSE: PLX), Infinity Pharmaceuticals, Inc. (NASDAQ: INFI)
The global cancer immunotherapy market by itself is expected to reach USD 118.8 billion by 2025 according
to Grand View Research Inc. The market is expected to benefit from introduction of newer drug classes, such as target receptors
for multiple myeloma and checkpoint inhibitors. "Increase in number of approvals for new immunotherapeutic drugs is driving
the global market. Introduction of new molecules has been proving to be beneficial for patients who are not responding to
chemotherapy. Several new immunotherapeutic options, such as immunomodulators and CAR-T cell therapy, are in the pipeline and are
being tested for their ability to provide better cancer treatment," Grand View Research indicates.
Cosmos Holdings Inc. (OTCQB: COSM) announced on November 16th that, "it has entered into
a $3 million securities purchase agreement with two institutional investors. "We are excited to
announce the addition of two institutional investors," said Grigorios Siokas, President and CEO of
Cosmos Holdings. "This agreement will provide us with capital to continue to grow our operations and expand our business."
The securities sold have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in
the United States absent registration or an applicable exemption from registration requirements.
This release is not used for the purpose of conditioning the market in the United States for any
of the securities offered."
About Cosmos Holdings, Inc. - Cosmos Holdings Inc. is a pharmaceutical company focused on identifying, acquiring, developing,
and commercializing medicines to improve patients' lives and outcomes. The Company has a trans-European network of over 110
clients and vendors expands to 16 countries including: Germany, United
Kingdom, Ireland, United Arab Emirates, Denmark, Italy, France, Singapore, Spain, Lebanon, Skopje, Jordan, Sweden, Poland, Netherlands, and AN or circumstances occurring after the date
hereof or the occurrence of unanticipated events or for any changes or modifications made to this press release or the
information contained herein by any third-parties, including, but not limited to, any wire or internet services.
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) is a specialty biopharmaceutical company focused on developing and
commercializing products in the therapeutic areas of respiratory disease and allergy. The company's current specialty
pharmaceutical products and product candidates include Epinephrine Injection pre-filled syringe product for use in the emergency
treatment of acute allergic reactions, including anaphylaxis; albuterol (APC-2000) and fluticasone (APC-4000) dry powder inhaler
products for the treatment of bronchospasm and asthma; and beclomethasone (APC-1000), a metered dose inhaler product for the
treatment of asthma. On June 15, 2017, the company announced that the U.S. Food and Drug
Administration has approved Adamis' EPINEPHRINE INJECTION, USP, 1:1000 (0.3 mg Pre-filled single dose syringe) for the emergency
treatment of allergic reactions (Type I) including anaphylaxis. The FDA has also approved the PFS trade name of Symjepi™.
CASI Pharmaceuticals, Inc. (NASDAQ: CASI) is a U.S. based, late-stage biopharmaceutical company focused on the
acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the
global market with a focus on commercialization in China. CASI's product pipeline features (1)
EVOMELA®, MARQIBO® and ZEVALIN®, all U.S. Food and Drug Administration (FDA) approved drugs in-licensed from Spectrum
Pharmaceuticals, Inc. for China regional rights, and currently in various stages in the
regulatory and clinical process for market approval in China, (2) its proprietary drug
candidate, ENMD-2076, ongoing in one Phase 2 clinical study, and (3) CASI-001 and CASI-002, proprietary preclinical candidates in
immuno-oncology. Recently, the company reported financial results for the three and nine months ended September 30, 2017. As of September 30, 2017, CASI had cash and cash equivalents
of approximately $21.6 million.
Protalix BioTherapeutics, Inc. (NYSE: PLX) is a biopharmaceutical company focused on the development and commercialization
of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®. Protalix's
unique expression system presents a proprietary method for developing recombinant proteins in a cost-effective, industrial-scale
manner. Protalix's first product manufactured by ProCellEx, taliglucerase alfa, was approved for marketing by the U.S. Food
and Drug Administration (FDA) in May 2012 and, subsequently, by the regulatory authorities of other
countries. Recnetly, the company announced two-year results from the phase I/II open-label extension clinical trial of
pegunigalsidase alfa, or PRX-102, for the treatment of Fabry disease will be presented at the New Horizons in Fabry Disease
Conference taking place November 24-25 in Prague, Czech Republic.
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) is an innovative biopharmaceutical company dedicated to advancing novel
medicines for people with cancer. Infinity is developing IPI-549, an oral immuno-oncology development candidate that selectively
inhibits PI3K-gamma. On November 10, 2017, the company reported Phase 1 clinical and translational
data for IPI-549, an oral, selective phosphoinositide-3-kinase-gamma (PI3K-gamma) inhibitor that targets immune-suppressive tumor
macrophages. These data from the recently completed monotherapy dose-escalation component of the Phase 1/1b study demonstrated
that IPI-549 dosed once daily (QD) was well tolerated and clinically active. Among 18 patients evaluable for activity, there was
a 44 percent clinical benefit rate, defined as patients who had remained on treatment for at least 16 weeks, including one
partial response in a patient with advanced peritoneal mesothelioma.
Subscribe Now! Watch us report from NYSE https://www.youtube.com/FinancialBuzzMedia
Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz
Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz
Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/
About FinancialBuzz.com
FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News,
Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company
Interviews. A pioneer in the financially driven digital space, video production and integration of social media,
FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination,
branding, marketing and advertising for third parties for corporate news and original content through our unique media platform
that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial
Publications.
Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not
undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the 'Site') is either original financial news or paid advertisements provided
[exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into
media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials
for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the
information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting
high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com
does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along
with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our
unique financial newswire and media platform. For this release, FinancialBuzz.com has been compensated three thousand dollars for financial news dissemination and pr services by a non-affiliate third party for
cosmos holdings inc. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this
editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon
engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com will always disclose any
compensation in securities or cash payments for financial news dissemination and PR advertising. FinancialBuzz.com does not
undertake to update any of the information on the editorial or Site or continue to post information about any companies the
information contained herein is not intended to be used as the basis for investment decisions and should not be considered as
investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any
security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions
expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes
electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own
independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By
accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may
be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to
purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any
investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a
particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation
needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment
decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are
subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness
are not guaranteed. For our full disclaimer, disclosure and Terms of Use. Please visit: http://www.financialbuzz.com .
For further information:
Media Contact: info@financialbuzz.com
+1-877-601-1879
Url: http://www.FinancialBuzz.com
SOURCE FinancialBuzz.com